Industry News
Biotechnology Industry News
Bayer has discontinued an…
Bayer has discontinued an early-stage clinical gene therapy for a rare genetic disorder in favor of a similar candidate.
UCB has entered the red-hot T-cell…
UCB has entered the red-hot T-cell engager space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.
The cash will be spread across…
The cash will be spread across four years to fund development of the anti-TL1A antibody duvakitug.
Ono Pharmaceutical subsidiary…
Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline, citing strategic reasons unrelated to the asset’s safety or efficacy.
The FDA has released the rejection…
The FDA has released the rejection letter explaining its recent refusal of Regenxbio’s gene therapy for the rare disease Hunter syndrome, providing further details into the agency’s issues with the biotech’s trial design.
As antibody discovery pipelines…
As antibody discovery pipelines scale, early developability assessment is increasingly used to support smarter candidate prioritization and downstream decision-making.
Theravance Biopharma will lay off…
Theravance Biopharma will lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.
Two new cancer cases have prompted…
Two new cancer cases have prompted Kyowa Kirin to shutter all studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory diseases.
Disc Medicine is laying off a…
Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate.
Biohaven is powering ahead with…
Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn that the company will need to be even stricter with its expenditures.
After cutting down its pipeline…
After cutting down its pipeline just a few months ago, OSE Immunotherapeutics is at it again, this time reorganizing as Boehringer Ingelheim walks away from the biotech’s metabolic dysfunction-associated steatohepatitis (MASH) candidate.
T-cell engager (TCE) specialist…
T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow Candid to trade on the Nasdaq while dumping RallyBio’s own rare disease maternal-fetal medicine assets.
More than a year after first…
More than a year after first agreeing to a reverse merger with Pulmatrix, protein degradation biotech Cullgen has instead opted to be bought by Gyre Therapeutics in a $300 million all-stock acquisition.
Shares of uniQure plummeted more…
Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for Huntington’s disease.
The FDA has liberated the second…
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following serious liver toxicity.
United Therapeutics has linked a…
United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial, setting the company up to seek FDA approval in pulmonary arterial hypertension
BioAtla is laying off 70% of its…
BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets.
Lynk Pharmaceuticals has reported…
Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema.
A second phase 3 study of…
A second phase 3 study of Roche’s fenebrutinib in relapsing multiple sclerosis has hit its primary endpoint, positioning the company to submit the BTK inhibitor for approval. But the discovery that more patients died on
Aardvark Therapeutics has seen its…
Aardvark Therapeutics has seen its share price halve in value after the company paused a phase 3 study of its lead metabolic asset over heart-related data.